Third-Generation Tyrosine Kinase Inhibitors and Beyond-Reference-Cited by-同舟云学术

Third-Generation Tyrosine Kinase Inhibitors and Beyond

Published:2010-10 Issue:4 Volume:47 Page:371-380
ISSN:0037-1963
Container-title:Seminars in Hematology
language:en
Short-container-title:Seminars in Hematology

Author:

Quintás-Cardama Alfonso,Kantarjian Hagop,Cortes Jorge

Publisher

Elsevier BV

Subject

Hematology

Reference77 articles.

1. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

2. International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib;Deininger;Blood,2009

3. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet;Baccarani;J Clin Oncol,2009

4. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis;de Lavallade;J Clin Oncol,2008

5. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia;Quintas-Cardama;Cancer Control,2009

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A new stability indicating ultra-fast liquid chromatographic (RP-UFLC) method for the quantification of Nilotinib – A drug for blood cancer;Research Journal of Pharmacy and Technology;2021-05-26

2. Dasatinib inhibits proliferation of liver cancer cells, but activation of Akt/mTOR compromises dasatinib as a cancer drug;Acta Biochimica et Biophysica Sinica;2021-05-07

3. A stability indicating method development and validation for separation of process related impurities and characterization of unknown impurities of tyrosine kinase inhibitor Nilotinib by RP-HPLC, NMR spectroscopy and ESI-MS;Materials Today: Proceedings;2021

4. Sínteses e propriedades de fármacos inibidores da tirosina quinase BCR-ABL, utilizados no tratamento da Leucemia Mieloide Crônica;Química Nova;2017-03-10

5. Targeted Therapy and Precision Medicine;Childhood Acute Lymphoblastic Leukemia;2017